EMA Authorised: Romvimza (vimseltinib dihydrate) — Deciphera Pharmaceuticals (Netherlands) B.V.

View source ↗

Summary

The European Medicines Agency authorized Romvimza (vimseltinib dihydrate) from Deciphera Netherlands for treatment of Giant Cell Tumor of Tendon Sheath, with or…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Giant Cell Tumor of Tendon Sheath

Drugs mentioned

• ROMVIMZA (vimseltinib)

Snippet

Status: Authorised. Therapeutic area: Giant Cell Tumor of Tendon Sheath. MAH: Deciphera Pharmaceuticals (Netherlands) B.V.. Decision date: 11/02/2026. Orphan medicine